Response by Gibson and Fox to Letter Regarding Article, "Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy"

Circulation. 2017 Jul 4;136(1):117. doi: 10.1161/CIRCULATIONAHA.117.028416.

Authors

C Michael Gibson¹, Keith Fox¹

Affiliation

¹ From Harvard Medical School, Boston, MA (C.M.G.); and University of Edinburgh, Scotland (K.F.).

PMID: 28674098
DOI: 10.1161/CIRCULATIONAHA.117.028416

No abstract available

Publication types

Letter
Comment

MeSH terms

Administration, Oral
Anticoagulants
Atrial Fibrillation*
Hospitalization
Humans
Rivaroxaban*
Vitamin K

Substances

Anticoagulants
Vitamin K
Rivaroxaban